(Q21851559)

English

BRAF V600E

genetic variant

VAL600GLU
V600E
RS113488022
V640E
VAL640GLU

In more languages

default for all languages

No label defined

No description defined

Statements

missense mutation

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

human chromosome 7

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

140453136

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

140453136

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

positive therapeutic predictor for

Dabrafenib / Trametinib combination therapy

medical condition treated

determination method or standard

CIViC evidence level B

CIViC 5-star trust rating

Vemurafenib / Gefitinib / Cetuximab combination therapy

medical condition treated

colorectal cancer

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1408

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Vemurafenib / Panitumumab combination therapy

medical condition treated

colorectal cancer

statement disputed by

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1413

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients

Vemurafenib / Panitumumab combination therapy

medical condition treated

colorectal cancer

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1589

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

Dabrafenib / Trametinib combination therapy

medical condition treated

non-small-cell lung carcinoma

determination method or standard

CIViC evidence level A

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3017

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

medical condition treated

colorectal cancer

determination method or standard

CIViC evidence level D

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/99

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

medical condition treated

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/757

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

medical condition treated

determination method or standard

CIViC evidence level B

CIViC 5-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1398

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

medical condition treated

colorectal cancer

statement disputed by

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1405

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

medical condition treated

determination method or standard

CIViC evidence level A

CIViC 5-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1409

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

medical condition treated

papillary thyroid cancer

determination method or standard

CIViC evidence level C

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1414

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib

medical condition treated

hairy cell leukemia

determination method or standard

CIViC evidence level B

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1579

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

medical condition treated

papillary thyroid cancer

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1591

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

medical condition treated

multiple myeloma

determination method or standard

CIViC evidence level C

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1698

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

medical condition treated

multiple myeloma

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1699

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

cobimetinib fumarate

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1141

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

vemurafenib / cobimetinib fumarate combination therapy

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1421

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

trametinib / vemurafenib / dabrafenib combination therapy

determination method or standard

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

gastrointestinal neuroendocrine tumor

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1430

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy

Irinotecan / Vemurafenib / Cetuximab combination therapy

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1902

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation

Dabrafenib / Trametinib combination therapy

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3758

Improved overall survival in melanoma with combined dabrafenib and trametinib

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5958

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5959

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5960

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

determination method or standard

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

laryngeal squamous cell carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5962

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

Panitumumab / Dabrafenib / Trametinib combination therapy

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6123

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer

Panitumumab / Trametinib combination therapy

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal adenocarcinoma

statement disputed by

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6124

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer

Sorafenib / Panitumumab combination therapy

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/89

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

irinotecan / Panitumumab / vemurafenib combination therapy

determination method or standard

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

cholangiocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5906

Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

statement disputed by

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1406

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1410

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Dabrafenib / Trametinib combination therapy

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6940

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Capecitabine / Vemurafenib / Bevacizumab combination therapy

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/98

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

Irinotecan / Vemurafenib / Cetuximab combination therapy

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/8506

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

erlotinib / vemurafenib combination therapy

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/8507

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2135

Improved survival with MEK inhibition in BRAF-mutated melanoma

determination method or standard

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

childhood pilocytic astrocytoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3777

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.

determination method or standard

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

ovarian serous carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3787

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation

Pertuzumab / vemurafenib combination therapy

determination method or standard

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

anaplastic thyroid cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5961

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

anaplastic thyroid cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6045

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

Dabrafenib / Trametinib combination therapy

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

anaplastic thyroid cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6975

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

cetuximab / encorafenib / binimetinib combination therapy

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7260

Interaction between cyclic adenosine monophosphate and cyclic gunaosine monophosphate in guinea pig ventricular myocardium

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

papillary thyroid cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/9018

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

Dabrafenib / Trametinib combination therapy

determination method or standard

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

cholangiocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5902

Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion

Dabrafenib / Trametinib combination therapy

determination method or standard

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

intrahepatic cholangiocarcinoma

2 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5903

Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5904

Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.

Dabrafenib / Trametinib combination therapy

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7264

A case of bronchial carcinoid with carcinoid syndrome (author transl)

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

Langerhans cell sarcoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7583

Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study

cetuximab / encorafenib / binimetinib combination therapy

determination method or standard

CIViC evidence level B

CIViC 5-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7612

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

Cetuximab / encorafenib combination therapy

determination method or standard

CIViC evidence level A

CIViC 5-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/9851

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

negative therapeutic predictor for

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/90

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/91

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

colorectal cancer

statement disputed by

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/816

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

colorectal cancer

statement disputed by

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/816

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2117

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2118

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2115

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

determination method or standard

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3827

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

positive diagnostic predictor for

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/79

Both BRAF V600E Mutation and Older Age (≥65 Years) are Associated with Recurrent Papillary Thyroid Cancer

papillary thyroid cancer

determination method or standard

CIViC evidence level B

CIViC 5-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/80

Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.

hairy cell leukemia

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1127

BRAF mutations in hairy-cell leukemia

negative prognostic predictor for

papillary thyroid cancer

determination method or standard

CIViC evidence level B

CIViC 5-star trust rating

statement disputed by

The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/102

The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/104

Prognostic value of BRAF mutations in localized cutaneous melanoma.

papillary thyroid cancer

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

papillary thyroid cancer

determination method or standard

CIViC evidence level B

CIViC 5-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/656

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence

colorectal cancer

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1552

Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis

papillary thyroid cancer

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

2 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2137

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

23 May 2022

https://civic.genome.wustl.edu/links/evidence/9170

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

colorectal cancer

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

3 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1940

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7156

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7157

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

multiple myeloma

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/463

Targeting the BRAF V600E mutation in multiple myeloma

colorectal cancer

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

statement disputed by

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2362

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

pediatric low-grade glioma

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7191

Pediatric low-grade gliomas can be molecularly stratified for risk

determination method or standard

CIViC evidence level B

CIViC 2-star trust rating

statement disputed by

BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/82

BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy

colorectal cancer

determination method or standard

CIViC evidence level B

CIViC 5-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/103

BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

ClinVar Variation ID

1 reference

ClinGen Allele Registry

http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA123643

14 November 2017

dbSNP Reference SNP number

152

1 reference

Ensembl transcript ID

ENST00000288602.6

1 reference

https://civic.genome.wustl.edu//links?idtype=variant&id=12

Google Knowledge Graph ID

0 references

HGVS nomenclature

NM_004333.4:c.1799T>A

2 references

ClinGen Allele Registry

http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA123643

14 November 2017

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

NC_000007.13:g.140453136A>T

2 references

ClinGen Allele Registry

http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA123643

14 November 2017

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

NP_004324.2:p.Val600Glu

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

ENST00000288602.6:c.1799T>A

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/12

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

Sitelinks

Wikipedia(3 entries)

enwiki V600E
fawiki V600E
nowiki V600E

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q21851559&oldid=2014771929"